Anika Reports Third Quarter 2019 Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/19/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Anthropic and Accenture partner on embedded AI safety evaluation
- Wells Fargo Downgrades Netflix (NFLX) to Underweight on Engagement Risks, 'We see tougher choices ahead'
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
Anika Therapeutics (ANIK) Tops Q3 EPS by 25c
October 24, 2019 4:36 PM EDTAnika Therapeutics (NASDAQ: ANIK) reported Q3 EPS of $0.64, $0.25 better than the analyst estimate of $0.39. Revenue for the quarter came in at $29.7 million versus the consensus estimate of $27.01 million.
Anika delivered double-digit revenue and earnings growth in the third quarter on the strength of growing global demand, Anikas expanding commercial platform, and... More
